Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 4 6Phase 3 6Phase 1 3Phase 1/2 1

Status

Unknown 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × icotinib × Clear all
NCT02024633 2015-07-15

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02278458 2015-05-22

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02066870 2015-03-13

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡